Protara Therapeutics Stock (NASDAQ: TARA)

Protara Therapeutics Stock (NASDAQ:TARA), Trade Ideas

Protara Therapeutics

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

Falling,Chart,As,A,Symbol,Of,Crisis.,Economic,Crisis.,Concept

Biotech

News

Health Care

Financing

Offerings

Movers

Trading Ideas

General

TARA

Explore TARA-002&#39;s data in NMIBC treatment. Discover findings from three trials, including response rates, adverse events, and future plans. Stay updated on Protara Therapeutics&#39; advancements in cancer therapy and FDA alignment for Choline Chloride.

Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equity

Penny Stocks

Protara Therapeutics Releases Early Cut Data From Investigational Cell-Based Therapy For Bladder Cancer

Long Ideas

Small Cap

Insider Trades

Markets

GRNA

KIND

NILE

The Dow Jones jumped by around 150 points on Monday. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Executives Buy Around $35M Of 4 Penny Stocks: Nextdoor, GreenLight Biosciences And More

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics Inc

Taraxa

Tarachi Gold Corp

TARANIS RESOURCES INC ORD by Taranis Resources Inc.

Taranis Resources Inc

Over the past 24 hours, Litecoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ltc/usd">LTC</a>) price has risen 3.53% to $79.18. This is contrary to its negative trend over the past week where it has experienced a 20.0% loss, moving from $98.14 to its current price. As it stands right now, the coin's all-time high is $410.26. 
The chart below compares the price movement and volatility for Litecoin over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1713294075_0.png" alt="price_chart" />
The trading volume for the coin has decreased 10.0% over the past week, while the overall circulating supply of the coin has increased 0.11% to over 74.43 million. This puts its current circulating supply at an estimated 88.61% of its max supply, which is 84.00 million. The current market cap ranking for LTC is #20 at $5.88 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1713294075_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$LTC

Litecoin Rises More Than 3% In 24 hours

Prominent cryptocurrency trader Altcoin Sherpa shared insights on Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) potential trajectory, anticipating new all-time highs down the line <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38269857/crypto-analyst-benjamin-cowen-says-bitcoins-16-dip-is-normal-but-this-time-it-could-develo">for the crypto king</a>.
What Happened: In an April 15 <a href="https://x.com/AltcoinSherpa/status/1779895476055134225">tweet</a>, the trader warned about a possible dip in Bitcoin's value to $53,000 if its high time frame closes below $60,000. He also adds that in this case, altcoins could potentially plunge by more than 50%.
However, he remains bullish on Bitcoin's long-term prospects, stating, &#8220;Bitcoin is still going to break all-time highs strongly later this year.&#8221;
Altcoin Sherpa advised traders to avoid leverage unless they are experienced or seeking to improve their skills, as the current environment is not conducive to it. Instead, he encouraged spending time on research and learning, as a major portion of the crypto market is down by over 50%.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38213103/peter-schiff-predicts-bitcoin-etfs-will-lead-to-its-biggest-crash-ever">Peter Schiff Predicts Bitcoin ETFs Will Lead To Its &#8216;Biggest Crash Ever&#8217;</a>
Why It Matters: These views come at a time of heightened volatility, prompting the trader to advise patience and confidence. He suggests a dollar-cost average strategy for projects that traders like, stating, &#8220;Buy some here, buy some there&#8230;don&#8217;t put all your buy in one area unless you&#8217;re actively trading.&#8221;
In the past 24 hours, Bitcoin long liquidations stand at $72.54 million, with $25 million of short positions liquidated as per Coinglass <a href="https://www.coinglass.com/LiquidationData">data</a>. Bitcoin Derivatives Data Analysis shows trading volume in the past 24 hours expanded by 11.5%.
IntoTheBlock data highlights a 2.1% surge in daily active addresses for Bitcoin, while a 41.7% increase was seen in large transaction volumes, reaching $59.2 billion. Transactions greater than 100,000 spiked to 11,709 as of April 15, up from 7,535 transactions on April 14. Despite the price dip, 86% of Bitcoin holders are currently in profit.
What's Next: The influence of <a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>  is expected to be thoroughly explored at Benzinga's upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38264619/altcoin-bloodbath-incoming-crypto-analyst-predicts-crash-similar-to-2019-after-ethb">Altcoin Bloodbath Incoming? Crypto Analyst Predicts Crash Similar To 2019 After ETH/BTC Support Breaks</a>
Image: Shutterstock

$BTC

New Bitcoin All-Time Highs Still To Come In 2024, Predicts Trader: 'Don't Put All Your Buy In One Area'

IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) has outperformed the market over the past 10 years by 13.2% on an annualized basis producing an average annual return of 23.57%. Currently, IDEXX Laboratories has a market capitalization of $40.86 billion. 
Buying $1000 In IDXX: If an investor had bought $1000 of IDXX stock 10 years ago, it would be worth $8,332.54 today based on a price of $492.00 for IDXX at the time of writing.
<h3>IDEXX Laboratories's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713294032_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IDXX

$1000 Invested In IDEXX Laboratories 10 Years Ago Would Be Worth This Much Today

Capital One Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) has outperformed the market over the past 15 years by 3.56% on an annualized basis producing an average annual return of 16.21%. Currently, Capital One Finl has a market capitalization of $52.05 billion. 
Buying $1000 In COF: If an investor had bought $1000 of COF stock 15 years ago, it would be worth $9,092.03 today based on a price of $136.84 for COF at the time of writing.
<h3>Capital One Finl's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713294027_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $9,100 Today

Want to watch our Cannabis Capital Conference live? For existing subscribers, you can get <a href="https://www.benzinga.com/events/cannabis-conference/livestream/">direct access</a>. For new users, you can get <a href="https://www.benzinga.com/events/cannabis-conference/livestream/">instant access here</a>

Cannabis

Events

Exclusives

MSOS

Dr. Chanda Macias Says When We Go To Europe We're At Mary-Jane Festival; We're Community Based; It Is About Connectivity To Local Markets; Let's Remove Corporate Veil And Get Back to Basics; If You're Not Supporting Legalization You Won't Make The Money You Think You Will

Pershing Square Capital Management Founder and CEO Bill Ackman has amassed over $4 billion in wealth by timing the markets correctly. The billionaire Harvard University graduate turned heads by predicting the global shutdown during the first wave of the COVID-19 pandemic, pocketing a 100-fold return on his $26 million investment, yielding roughly $2.6 billion in just a month.&nbsp;
In 2023, Pershing Square's total returns stood at nearly 27%, beating the benchmark S&amp;P 500 index's annual returns last year.&nbsp;
<h2 class="wp-block-heading">Ackman's Journey From Harvard To Wall Street&nbsp;</h2>
Ackman's Pershing Square Capital has roughly $16 billion in total assets under management invested across seven stocks.&nbsp;
&#8220;Everyone told me it was a really stupid idea to start my own hedge fund right out of business school. That's how I knew that it was a good idea,&#8221; Ackman said.&nbsp;
Don't Miss:
<ul>
<li>Investing in real estate just got a whole lot simpler. This <a href="https://www.benzinga.com/go/bezos-landlord">Jeff Bezos-backed startup will allow you to become a landlord</a> in just 10 minutes, and you only need $100.</li>
<li>Want To Grow Your Wealth Passively? Unlock Real Wealth with <a href="https://www.benzinga.com/money/cityfunds-yield">Cityfunds&#8217; Exclusive 8% Yield Fund</a>.</li>
</ul>
But his journey hasn't always been smooth. In a high-stakes saga that unfolded in 2017, Elliott Investment Management, one of the largest activist hedge funds in the world with over $93 billion in total assets under management, set its sights on Pershing Square Holdings.&nbsp;
In a strategic move, Elliott made a bold investment into Pershing Square Holdings, a closed-end vehicle trading below its asset value nearly seven years ago. Elliott's maneuver involved taking a significant position in Pershing Square while simultaneously shorting the fund&#8217;s underlying securities. This calculated gamble was designed to drive Pershing Square to the ground, forcing it to go belly up.&nbsp;
&#8220;I envisioned an end where the permanent capital vehicle ends up getting liquidated, and another activist in my industry puts me out of business,&#8221; Ackman said.
Yet, Ackman was not one to yield easily. His defense included buying shares of Pershing Square in the market to retain control, ensuring the hedge fund's value didn't plummet in the open market.&nbsp;&nbsp;
Ackman credits JPMorgan Chase &amp; Co. for this success, as the bank's $300 million loan allowed him to survive in the high-stakes turmoil on Wall Street.&nbsp;&nbsp;
&#8220;I give JPMorgan enormous credit in seeing through it,&#8221; he said. &#8220;It's a handshake bank and they bet I'd succeed.&#8221;
Trending
<ul>
<li>Want to Create a Passive Income Stream? <a href="https://www.benzinga.com/go/grow-wealth-passively">These High-Yield Real Estate Notes Might Be Your Holy Grail</a></li>
</ul>
<h2 class="wp-block-heading">Ackman's Relationship With Dimon&nbsp;</h2>
JPMorgan was under the leadership of Jamie Dimon when it loaned Ackman $300 million to save his fund. Suffice it to say, the Harvard-trained hedge fund manager has nothing but praise for the CEO of the world's largest bank.&nbsp;
In a bold post on X last May, Ackman touted Dimon as a "no bullsh&#x2A;t, straight-talking charismatic leader" who should run for president.
"Our country is at risk with $32 trillion of debt with no end to massive deficits in sight, heading into a recession at a time of great political uncertainty. We need an exemplary business, financial and global leader to manage through what is likely to be a critically important decade for our country in determining our destiny," Ackman said. "Jamie Dimon is that leader."
Ackman isn't the only one who envisions Dimon in a political landscape. Former President Bill Clinton has also advocated for the banking executive's potential, stating,&nbsp; "If he decides to get out of banking, I think he would be really good in politics."
&nbsp;Read Next:
<ul>
<li>Elon Musk Is Bullish On Austin. Here&#8217;s <a href="https://www.benzinga.com/go/musk-austin">How To Invest In The City&#8217;s Growth Before He Floods It With New Tech Workers</a>.</li>
<li>Whole Foods&#8217; Landlord Has Achieved A 15% Net IRR For Accredited Investors Since 2015 — <a href="https://www.benzinga.com/go/whole-foods-landlord">Discover The Latest Investment Opportunities On Its Platform</a>.</li>
</ul>

Real Estate

Bill Ackman's Journey To Become A Billionaire Wasn't Easy — A $300 Million Handshake Deal With Jamie Dimon Saved Him

Shiba Inu's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) price has increased 4.97% over the past 24 hours to $0.000022, which is in the opposite direction of its trend over the past week, where it has experienced a 20.0% loss, moving from $0.000028 to its current price. 
The chart below compares the price movement and volatility for Shiba Inu over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1713294005_0.png" alt="price_chart" />
The trading volume for the coin has increased 54.0% over the past week while the overall circulating supply of the coin has increased 0.11% to over 589.26 trillion. The current market cap ranking for SHIB is #12 at $13.19 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1713294005_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$SHIB

Shiba Inu's Price Increased More Than 4% Within 24 hours

Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares are trading higher Tuesday. Here's a <a href="https://www.benzinga.com/markets/cannabis/24/04/38207295/fed-funded-study-finds-increase-in-medical-marijuana-patient-enrollments-chronic-pain-most-commo">look at what's going on.&nbsp;</a>
The Details:
Cannabis companies' stocks have rallied recently on renewed optimism that the DEA may reschedule marijuana to a Schedule III substance.&nbsp;
Last week, FDA Commissioner Robert Califf&nbsp; told a House committee that there is&nbsp; "no reason" for the DEA to delay the rescheduling of marijuana from Schedule 1 to Schedule 3 of the Controlled Substances Act. He also <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38226873/analyst-reacts-to-fda-commish-comments-medical-and-recreational-cannabis-could-have">suggested</a> medical and recreational marijuana could have separate regulations.&nbsp;
Tilray has been a frequent trending stock on WallStreetBets as of late, and last week CIBC analyst John Zamparo maintained Tilray with a Neutral rating and lowered the price target from $2.25 to $2.00.
Related News: <a href="https://www.benzinga.com/news/24/04/38255034/whats-going-on-with-rivian-automotive-stock">What&#8217;s Going On With Rivian Automotive Stock?</a>
<h2 class="wp-block-heading">TLRY Stock Forecast in 2030: </h2>
Predicting the future in stock prices over long periods of time is challenging. Wall Street analysts use complex models that take into account interest rates, economic growth, competitive advantages, management teams and historical profitability, among a host of other factors.
If, as an investor, you want to assume most of the major factors remain stable, you can use trend analysis as a helpful tool. Using a longer term trend line or historical performance of the stock, you can aim to forecast a stock's annual rate of return.
For Tilray Brands, over the past 5 years, it's annualized stock performance is -48.47%, and if you assume that trend continues for another 5 years, you can expect a stock to trade at $0.07.
Using a trend line (see how to <a href="https://www.benzinga.com/23/01/30335939/a-guide-on-how-to-identify-trend-reversals">perform this function here</a>), If you choose to use a trend line, connect your two points and look into the future to the point in time in which you're curious. Once you've identified that stock price, you may want to consider what type of conditions would need to exist for the stock to justify the share price &#8211; be it an outside influence or managerial decision making.
TLRY Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Tilray Brands shares are up 4.49% at $1.86 at the time of publication Tuesday.
Image: 7raysmarketing from Pixabay

TLRY

What's Going On With Marijuana Grower Tilray's Stock?

ISPR

Luna Stower Says Going To DC Next Week; We're Lobbying; We Need To Have Big Boys In The Room And Be The Big Boys In The Room; We're Part Of A Bigger Environment And Push To The Top

Microsoft Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) LinkedIn lets job seekers post &#8220;open to work&#8221; banners on their profiles to let employers know they are searching for jobs. But, activating it <a href="https://www.benzinga.com/news/23/07/33352218/you-have-zero-chance-of-getting-hired-if-this-is-on-your-resume-says-former-google-recruiter-1">could be a mistake</a>.
What To Know: Former Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) recruiter and current CEO of FairComp Nolan Church believes posting an &#8220;open to work&#8221; banner on your LinkedIn page is &#8220;the biggest red flag&#8221; as a job candidate, per <a href="https://www.cnbc.com/2024/04/15/should-you-use-linkedins-open-to-work-banner-experts-disagree.html">CNBC</a>. 
"There is a truism in recruiting that the best people are not looking for jobs," Nolan said.
He&#8217;s not alone in his thinking. Former Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) recruiter Lindsay Mustain believes recruiting is all about power dynamics. Recruiters want to want you, not the other way around, she said. 
Activating the &#8220;open to work&#8221; banner on LinkedIn shows that you are in need of something, which can be a turn-off and gives potential employers all of the power in conversations, Mustain explained. 
Don&#8217;t Miss: <a href="https://www.benzinga.com/general/23/11/35921237/most-people-mistakenly-leave-out-the-best-predictor-of-future-success-on-their-resumes-says-former-g">Most People Mistakenly Leave Out The Best &#8216;Predictor Of Future Success&#8217; On Their Resumes, Says Former Google Recruiter</a>
So what does that mean for the more than 33 million LinkedIn users who are currently using the &#8220;open to work&#8221; banner on their profiles? Well, LinkedIn tends to disagree with the hiring experts, but the data is unclear.
LinkedIn can&#8217;t see how many job offers come as a result of a candidate posting the banner on their profile, but message data appears to tell a different story. 
Those who post the &#8220;open to work&#8221; banner on the business-focused <a href="https://www.benzinga.com/topic/social-media-platforms">social media</a> platform are twice as likely to get messaged by a recruiter and are about 20% more likely to get a message from the broader LinkedIn community. 
However, this may be due to a bump in visibility for smaller companies. Many small businesses don&#8217;t pay up for the recruiter tools on LinkedIn, so the banners can help them identify prospective candidates.
Ultimately, it&#8217;s going to depend on the company and the hiring manager&#8217;s preferences. Some may find it helpful, while others may see it as a red flag. 
Career coach Phoebe Gavin told CNBC that what really matters in a <a href="https://www.benzinga.com/topic/social-media">LinkedIn</a> profile is having a list of titles, achievements, keywords and featured links that can show how involved you are in your industry. 
&#8220;If you have ‘open to work' up but your profile is a wasteland, it's not going to make a difference at all. Because even if a recruiter finds you, they're not going to learn anything useful,&#8221; Gavin said.
Read Next: <a href="https://www.benzinga.com/news/24/04/38264187/elon-musk-says-charging-new-x-users-a-small-fee-is-the-only-way-to-curb-bot-onslaught">Elon Musk Says Charging New X Users A &#8216;Small Fee&#8217; Is The Only Way To Curb Bot Onslaught</a>
This story is part of a series of features on the subject of success,&nbsp;<a href="https://www.benzinga.com/topic/benzinga-inspire">Benzinga Inspire</a>.
Photo: <a href="https://www.flickr.com/photos/197820335@N04/">Jérémy from HelpIn</a>/Flickr.

Social Media

AMZN

GOOG

GOOGL

MSFT

LinkedIn's 'Open To Work' Banner Is 'Biggest Red Flag' When It Comes To Landing A Job, Says Former Google Recruiter

Luna Stower Says We Are First Vape Company To IPO; Conscious About Way We Show Up; Exciting To Play On That Stage; Coming Into Cannabis And Bringing Real World Experience With Spreadsheet And Institutional Funding; There Are People Really Want To Help Who Trust You

"The cannabis industry is very tight-knit and trust-based, so there is nothing more valuable than a solid customer referral." That's according to Amar Singh, CEO and co-founder of Elevated Signals, a provider of manufacturing software designed for the complex operations of fast-growing manufacturing businesses.
Singh got it right. Partnerships, trust and doing business in good faith are what those joining Benzinga's cannabis event in Florida this week are about to witness.
<figure class="wp-block-image aligncenter size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/16025119/2231044_CCCFloridaGIF_V2_031124-1-36.gif" alt="" class="wp-image-293191" /></a></figure>
Elevated Signals recently reported securing CA$7.9 million ($5.7 million) in Series A funding. The investment led by Yaletown Partners, with participation from Third Kind Venture Capital, WGD Capital, Colin Harris, Raiven Capital, and Pareto Holdings is slated to help the company expand and diversify in terms of the industries it serves.
"Elevated Signals is solving a real problem for its customers and is aligned with larger trends in the market," Hans Knapp, general partner and co-founder at Yaletown Partners said recently.
But, it all started with cannabis. The company&#8217;s manufacturing software was pioneered in the highly regulated and vertically integrated cannabis industry in Canada.
See also: <a href="https://www.benzinga.com/markets/cannabis/23/05/32560252/edibles-company-teams-up-with-software-provider-to-get-things-moving-quicker-in-the-kitchen-and-">Edibles Company Teams Up With Software Provider To Get Things Moving Quicker In The Kitchen And Out The Doo</a><a href="https://www.benzinga.com/markets/cannabis/23/05/32560252/edibles-company-teams-up-with-software-provider-to-get-things-moving-quicker-in-the-kitchen-and-">r</a>
"We networked our way into early relationships with several influential licensed producers in British Columbia and worked very closely with their teams to build our initial version of the software," Singh told Benzinga. "This gave us a safe sandbox to test and launch with trusted partners, which built our reputation as reliable innovators and then led to introductions to other customers"
<h3 class="wp-block-heading">What Elevated Signals Is All About</h3>
Today, Elevated serves a growing list of sectors that range from controlled environment agriculture to natural health product manufacturing, critical minerals recovery and mining, to name a few.
Its manufacturing software replaces systems of spreadsheets, paper and outdated software with a fully digital centralized platform that manages inventory, quality recordkeeping, compliance and environmental data.
Moreover, its GMP-validated system enables improvements to supply chain visibility, operational productivity, and yield optimization.
By capturing and utilizing granular inventory data and scientific and process data associated with that inventory, Elevated is enhancing manufacturing efficiency, implementing predictive maintenance, optimizing inventory management, reducing operational costs and improving product quality, Singh explained.
"By analyzing and acting on this data, our customers can identify and address bottlenecks, minimize waste, and ensure their processes are as efficient and effective as possible," he added.
But, what differentiates Elevated Signals from larger competitors in the technology industry?
Singh said "time to value" and "ease of use."
"We can get customers up and running in two weeks to two months depending on the size of the client, compared to large ERP software timelines that are typically 6-12 months or longer," he noted. "We also have a near perfect implementation record versus large ERP implementations, which fail 75% of the time according to Gartner."
Now read: <a href="https://www.benzinga.com/markets/cannabis/23/03/31256964/new-zealands-largest-medical-cannabis-cultivator-puro-selects-elevated-signals-as-its-seed-to-sa">New Zealand&#8217;s Largest Medical Cannabis Cultivator, Puro, Selects Elevated Signals As Its Seed-To-Sale Software Provider</a>

Interview

It All Started With Cannabis: How This Innovative Manufacturing Software Firm Is Solving 'Real' Problem For Its Customers

Morgan Stanley analyst Simon Flannery maintains Gogo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOGO#NASDAQ">GOGO</a>) with a Equal-Weight and lowers the price target from $15 to $12.

Price Target

Analyst Ratings

GOGO

Morgan Stanley Maintains Equal-Weight on Gogo, Lowers Price Target to $12

Resideo Technologies Inc&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REZI#NYSE">REZI</a>) recent acquisition of Snap One Holdings Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPO#NASDAQ">SNPO</a>) has sparked investor interest. On Monday, Snap One announced it will be acquired by Resideo Technologies for <a href="https://www.benzinga.com/quote/REZI/news">$1.4 billion in cash</a>.
We covered the news first here: <a href="https://www.benzinga.com/markets/equities/24/04/38246312/why-is-snap-one-stock-jumping-premarket-monday">Why Is Snap One Stock Jumping Premarket Monday?</a>
Analyst Cory A. Carpenter from JPMorgan provided valuable insights on the acquisition, calling it a &#8220;strong strategic fit at reasonable value.&#8221;
Let&#8217;s delve into the implications for both Resideo and Snap One investors:
<h2 class="wp-block-heading">Resideo Stock &#8211; 35% Upside In Sight</h2>
<ul>
<li>Strategic Fit: Carpenter sees a strong strategic fit between Resideo&#8217;s ADI distribution business and Snap One. Both companies target the smart living market, with Resideo focusing on commercial security ,and Snap One primarily serving the home technology vertical.</li>
<li>Financial Perspective: The acquisition price of $10.75 per share for Snap One aligns with Carpenter's earlier fair value estimate of $11. This price is deemed reasonable, equating to about 10 times the projected 2024 adjusted EBITDA before merger synergies and 7.5 times including synergies.</li>
<li>Revenue Expectations: Resideo&#8217;s preliminary Q1 results indicate revenue at the midpoint of its prior outlook, suggesting continued improvement in profit and loss.</li>
<li>Long-term Outlook: Carpenter maintains an Overweight rating on Resideo stock, with a price target of $27. This represents a 35% upside from current price levels. Carpenter anticipates enhanced revenue and gross margin profiles over time, driven by synergies from the Snap One acquisition.</li>
</ul>
<h2 class="wp-block-heading">Snap One &#8211; Uniquely Strategic To Resideo&#8217;s Business</h2>
<ul>
<li>Complementary Verticals: Carpenter highlights the complementary nature of Snap One and Resideo&#8217;s vertical footprints. He emphasized potential for higher service professional wallet share and retention.</li>
<li>Distribution Expansion: Snap One&#8217;s acquisition by Resideo is expected to significantly expand the distribution of its products. Snap One can leverage Resideo&#8217;s physical footprint.</li>
<li>Financial Benefits: Snap One&#8217;s higher gross margin and adj. EBITDA margin, along with Resideo&#8217;s identified $75 million annual run-rate synergies, are anticipated to enhance profitability and drive long-term growth.</li>
<li>Regulatory and Financial: Carpenter doesn&#8217;t anticipate any regulatory hurdles or competing bids for Snap One. The merger agreement and financial terms provide stability and confidence in the deal&#8217;s completion.</li>
</ul>
Resideo&#8217;s acquisition of Snap One presents a compelling strategic opportunity for both companies. Carpenter&#8217;s insights shed light on the potential benefits for investors in the evolving landscape of smart living technology.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38273842/s-p-500-due-for-classic-10-correction-wall-street-veteran-warns-why-they-expect-zer">S&amp;P 500 Due For &#8216;Classic 10% Correction,&#8217; Wall Street Veteran Warns: Why They Expect Zero Rate Cuts In 2024</a>
Image generated using artificial intelligence using Midjourney.

Analyst Color

Tech

REZI

SNPO

Resideo's $1.4B Purchase Of Snap One Is A 'Strong Strategic Fit': JPMorgan Sees 35% Upside

Former U.S. Sen. Cory Gardner told a panel on the first day of the <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference</a> in Florida that several ranking Congress members are intending to attach the <a href="https://www.benzinga.com/topic/secure-and-fair-enforcement-safe-banking-act">SAFER Banking Act </a>to the must-pass Federal Aviation Administration reauthorization.
"It might not be pretty but it will get the job done," the Colorado Republican told the Benzinga conference. 
During the same panel, former U.S. Rep. Ed Perlmutter hinted at imminent regulatory changes that could benefit the cannabis industry, stating: &#8220;The DEA will help with 280E and so forth, and hopefully we&#8217;ll see a decision this week, or soon.&#8221;
Shares of the cannabis-focused ETF AdvisorShares Pure US Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>), surged midday Tuesday in what could be reaction to the remarks made at the Benzinga conference. 
What Happened: House Financial Services Chair Patrick McHenry (R-N.C.) and U.S. Rep. Maxine Waters (D-CAO) met recently with Senate Majority Leader Chuck Schumer (D-NY) to discuss stablecoin legislation, and the idea of cannabis banking legislation also being attached to the upcoming FAA reauthorization bill came up.
Gardner stressed the crucial importance of growing bipartisan support for Safer Banking. 
&#8220;We have to prove to Sen. Schumer and to Sen. McConnell that we&#8217;ve got the votes on our own merit to get this through.&#8221; The FAA reauthorization and other legislation will lead to negotiations, Gardner said: &#8220;Once we have that level of support, I believe we&#8217;re there.&#8221; Change comes slowly, and cannabis is a &#8220;heavy lift&#8221; in Washington, D.C., he added. 
<h2 class="wp-block-heading">How Close Are We To Cannabis Banking Reform?</h2>
Gardner shared an anecdote from his early days in D.C. when he was told that major pieces of legislation take an average of 10 years to pass. 
"But there's good news here though … we're at year 10,&#8221; he said. 
Former U.S. Rep. Ed Perlmutter, a Colorado Republican, who has been at the <a href="https://www.benzinga.com/markets/cannabis/24/02/36914483/former-congressman-ed-perlmutter-joins-team-of-federal-policy-advisors-at-cannabis-reform-advoca" target="_blank" rel="noreferrer noopener">forefront of cannabis banking reform</a> since he introduced the<a href="https://www.benzinga.com/topic/secure-and-fair-enforcement-safe-banking-act" target="_blank" rel="noreferrer noopener"> SAFE Banking</a> Act in 2013, responded to panel moderator Saphira Galoob of the National Cannabis Roundtable, who asked how close are we to seeing banking reform.
"We're closer than ever," said Perlmutter, who referenced the September 2023 approval by the Senate Banking Committee <a href="https://www.benzinga.com/markets/cannabis/23/09/34929327/breaking-senate-committee-approves-cannabis-banking-reform-in-historic-vote">of the SAFER Banking Act</a> that had been in the works for nearly a decade.  
"This is a major piece of legislation and on the two paths — rescheduling and legislation — we're farther along than we've been in 50 years. That doesn't mean we're done, we've got a lot of work to do but we are on the cusp," he said.
Lauren Niehaus, Trulieve (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTCQX">TCNNF</a>)&#8217;s director of government relations, said that "when we meet with our members of Congress, we think we're the most important issue in the room, but they have hundreds of thousands of issues they're dealing with, so it's an uphill battle and it's steep, but that doesn't mean we're not getting there."
John Sullivan, executive VP of Cresco Labs (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTCQX">CRLBF</a>), said that although it can take 11 years to pass a piece of legislation, a lot has changed in the last three years. He referred to President Joe Biden as a "reluctant cannabis person."
&#8220;But we all know that cannabis wins on the merits,&#8221; Sullivan said. &#8220;There is no doubt that cannabis by and large is beneficial to society. It helps people with all different kinds of ailments, it helps people relax, and for 5,000 years the plant hasn&#8217;t killed anybody. So we need to keep talking to our legislators about it.&#8221;
Javier Hasse contributed to this report. 
Former U.S. Sen. Cory Gardner, center, with former U.S. Rep. Ed Perlmutter, left, and Cresco Labs executive vice president John Sullivan, right, at the Benzinga Cannabis Capital Conference April 16, 2024 in Hollywood, Florida. Photo by Quentin Dupree.

Government

Regulations

Specialty ETFs

Politics

ETFs

CRLBF

TCNNF

Cannabis Banking Reform 'Closer Than Ever,' D.C. Insiders Tell Benzinga Conference: Cannabis ETF On The Move Tuesday

Heather Molloy Says Hard To Raise Money If You're A Woman In Cannabis Industry; Ability To Work With Companies And Act As Bridge To Be Super Exciting; Value I Can Add Is Trying To Help Deals Get Done And Help Capital Get Into Those Businesses

Heather Molloy Says Investing In U.S. Hoping These Companies Can Work Overseas

Heather Molloy Says Recent Investment Have Been Hemp Companies That Provide Terpenes Used In Vape Or Beverage Or Other Products At A National Scale CPG Level That Allow You To Go International; Lack Of Capital In Space Makes Going International Complicated

From Benzinga's Cannabis Capital Conference: Speedwell Partners Founder And Managing Partner Heather Molloy Says Cannabis Industry Really Complicated On State-By-State And Local Market Basis; As Investor Looking For Certain Angles That Allow Brands To Scale Internationally

Houseplant cannabis brand co-founded by Seth Rogen, Evan Goldberg and Michael Mohr is now accessible via the instant delivery application Gopuff. Under this new collaboration, Gopuff will exclusively carry a new, limited edition Houseplant Glass Ashtray – available for delivery in minutes. 
"It's our goal for everyone to have Houseplant products in their homes" stated Mohr. "We&#8217;re thrilled to be working with GoPuff, which significantly increases access to our products and provides instant distribution for millions of people thanks to the hundreds of micro-fulfillment centers they have across the country. With quick and efficient deliveries, more people than ever can now get select Houseplant products delivered in minutes."
Houseplant offers a wide variety of smoking accessories, lifestyle and home goods. As Houseplant's first national instant delivery partner, Gopuff is now delivering the brand's popular products to customers&#8217; doors in minutes along with thousands of everyday essentials. 
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="1024" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/16033618/Flip-Lighter-Green-1024x1024.png" alt="" class="wp-image-293263" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/16033618/Flip-Lighter-Green-1024x1024.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/16033618/Flip-Lighter-Green-300x300.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/16033618/Flip-Lighter-Green-150x150.png 150w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/16033618/Flip-Lighter-Green-768x768.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/16033618/Flip-Lighter-Green.png 1080w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Gopuff will be the exclusive retailer of a new, limited-edition custom design of the Houseplant Glass Ashtray, priced at just $25. The brand new <a href="https://www.benzinga.com/markets/cannabis/24/01/36767778/seth-rogens-houseplant-partners-with-ocb-for-exclusive-eco-friendly-rolling-paper-line" target="_blank" rel="noreferrer noopener">Houseplant by OCB rolling paper</a>s are stocked and available in the smoke shop. 
<h2 class="wp-block-heading">Houseplant On Gopuff&nbsp;</h2>
The full Houseplant collection on Gopuff will initially consist of seven premium items, including:
<ul>
<li>Fliptop Lighter ($40)</li>
<li>Glass Candle ($45)</li>
<li>Houseparty Double LP ($55)</li>
<li>Ashtray Set by Seth ($98)</li>
<li>Pebble Match Strike ($95)</li>
<li>Houseplant by OCB Classic 1 1/4 Rolling Papers + Tips ($3.99)</li>
<li>Houseplant by OCB Classic Cone 1 1/4 6 Pack ($3.49)</li>
</ul>
"Through strategic partnerships with culturally-connected brands like Houseplant, we are expanding our product offerings, ensuring our customers have easy access to what they want, when they want it," stated Daniel Folkman, SVP of business at Gopuff. "This unique collaboration between Gopuff and Houseplant embodies a seamless intersection of style, convenience, culture and commerce." 
Gopuff customers are also invited to shop a selection of food and beverage products curated by Houseplant. Included in this limited-time-only assortment are items like Topo Chico seltzer water, pink salt popcorn, Skinny dipped almonds and more.&nbsp;
Now Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/cannabis/23/01/30651350/smoke-weed-with-seth-rogen-make-a-ceramic-ashtray-with-him-spend-the-night-airbnb-is-hosting" rel="noreferrer noopener">Smoke Weed With Seth Rogen, Make A Ceramic Ashtray With Him &amp; Spend The Night, Airbnb Is Hosting</a>
Courtesy photos&nbsp;

Seth Rogen's Cannabis & Lifestyle Brand Houseplant Available On Instant Delivery App Gopuff

Overall market sentiment has been high on Protara Therapeutics Inc (TARA)  stock lately. TARA receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator. Protara Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on TARA!See Full TARA ReportWh

Should You Buy Protara Therapeutics Inc (TARA) Stock on Friday?

Protara: A Bombed Out Biotech With A Very Positive Skew

In a report released today, Stacy Ku from TD Cowen maintained a Buy rating on Protara Therapeutics (TARA – Research Report), with a price target of...

Buy Rating on Protara Therapeutics Backed by Promising TARA-002 Clinical Trials and Significant Market Opportunity

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cadrenal Therapeutics, Inc. (CVKD – Research Report), Protara The...

Analysts Conflicted on These Healthcare Names: Cadrenal Therapeutics, Inc. (CVKD), Protara Therapeutics (TARA) and Spruce Biosciences (SPRB)

Protara Therapeutics (TARA) just unveiled an announcement. Protara Therapeutics, Inc. has announced the resignation of their Chief Medical Officer,...

Protara Therapeutics CMO Resigns, Interim Successor Named

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
If you want to strike it rich via stocks to help you retire on a private island, the reality is this: You probably can&rsquo;t go the buy-and-hold approach that legendary investors like Warren Buffett deploy. For one thing, that was a different time when the &ldquo;American Dream&rdquo; was accessible to any hardworking, industrious individual. Now, speculation is the name of the game.



Again, the context here is making it filthy rich. More than likely, you can&rsquo;t do that by acquiring shares of blue-chip <a href="https://investorplace.com/stock-types/dividend-stocks/">dividend stocks.</a> You need something with pizazz, something that provides significant pop. But in doing so, you must accept a gargantuan magnitude of uncertainty.



Basically, it&rsquo;s a countervailing relationship: The more certainty you have toward an investment, the less its potential reward. The more uncertainty, the greater the potential reward &mdash; but at the cost of substantial downside risk.



If you can handle this equation, these stocks might be for you.



<h2>Rigetti Computing (RGTI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/09/quantum-computing-3-300x169.jpg" alt="A concept image showing a quantum computer with a matrix background; quantum computing. leading quantum stocks, quantum computing stocks to buy"><div>Source: Shutterstock</div></div>A Berkeley, California-based developer of quantum integrated circuits, Rigetti Computing (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgti-stock-quote/">RGTI</a>) represents one of the top ideas for stocks to retire on a private island. Thanks to its clear relevance to quantum computing, at the very least, RGTI stock benefits from a compelling narrative. In particular, as artificial intelligence pushes the boundaries of classical computers, the tech industry may push for a paradigm shift.



Indeed, the market has caught onto the opportunity. Since the start of the year, Rigetti gained 69%. Over the past 52 weeks, it nearly tripled its market value. However, the company represents an intriguing cocktail, missing bottom-line expectations in some quarters while beating in others last year. Overall, the average surprise in fiscal 2023 came out to 3.53% below parity.



For the current fiscal year, experts believe Rigetti will post a loss per share of 40 cents on sales of $16.1 million. That would be a sizable improvement over last year&rsquo;s loss of 57 cents per share on revenue of $12 million.



Analysts rate RGTI a <a href="https://www.tipranks.com/stocks/rgti/forecast">unanimous Strong Buy</a> with a $3.25 average price target, implying 92% upside potential.



<h2>DZS Inc. (DZSI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/cloud-computing-phone-300x169.png" alt="An image of a hand holding a phone with a cloud on the screen, icons above the phone; controller, music note, camera, plane, shopping cart, home, magnifying glass. Cloud computing stocks to buy"><div>Source: La1n/Shutterstock</div></div>Listed under the technology industry label &mdash; in particular, communication equipment &mdash; DZS Inc. (NASDAQ:<a href="https://investorplace.com/stock-quotes/dzsi-stock-quote/">DZSI</a>) provides access and optical networking infrastructure and cloud software solutions in the Americas, Europe, the Middle East, Africa and Asia. Per its <a href="https://finance.yahoo.com/quote/DZSI/profile">corporate profile,</a> DZS offers access edge solutions through DZS Velocity, including voice, high-definition and ultra-high-definition video, highspeed internet access and business class services.



Since the start of the year, DZSI stock incurred a loss of over 32% of equity value. In the past 52 weeks, it&rsquo;s down 84%. Financially, the performance doesn&rsquo;t get much better. It has consistently underperformed bottom-line expectations in the past, making it a tough idea to even talk about (unless you&rsquo;re clear about the context of stocks to retire on a private island).



Still, there may be some hope for a turnaround. For fiscal 2024, experts believe the company will post earnings per share of 67 cents on revenue of $425.4 million. For context, in 2022, the company suffered a loss per share of $1.33 on <a href="https://www.gurufocus.com/stock/DZSI/financials?search=dzsi">sales of $375.7 million.</a>



Conspicuously, analysts also peg shares a <a href="https://www.tipranks.com/stocks/dzsi/forecast">unanimous Strong Buy</a> with a $6.50 price target, implying 400% upside potential.



<h2>Protara Therapeutics (TARA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/medical-tools-tech-therapeutics-300x169.png" alt="An image of a tablet with 'therapeutics' on the screen, a stethoscope and face mask around it"><div>Source: ra2 studio/Shutterstock</div></div>Based in New York City, Protara Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/tara-stock-quote/">TARA</a>) is a clinical-stage biopharmaceutical company. Per its <a href="https://finance.yahoo.com/quote/tara/profile">corporate profile,</a> Protara engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company&rsquo;s lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations.



Unlike some other candidates for stocks to retire on a private island, TARA is off to a great start in 2024. Since the beginning of January, it&rsquo;s up 109%. It&rsquo;s a wildly trading entity, though, with shares gaining only about 10% in the past 52 weeks. You&rsquo;ve got to have a strong stomach for this opportunity.



Surprisingly, though, the company only missed bottom-line expectations once last fiscal year. In Q2, it posted a loss per share of $1 against an expected per-share loss of 87 cents. However, it mitigated the red ink in the other quarters. Overall, the average surprise landed at 1.9%.



To be fair, Protara is a pre-revenue enterprise and may stay that way for a while. However, analysts rate shares a <a href="https://www.tipranks.com/stocks/tara/forecast">Moderate Buy</a> with a $36.50 price target, implying an 836% upside potential.



On the date of publication, Josh Enomoto did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines.</a>
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/03/3-stocks-that-could-help-you-retire-on-a-private-island/">3 Stocks That Could Help You Retire on a Private Island</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Stocks That Could Help You Retire on a Private Island

Protara Therapeutics (TARA) has provided an announcement. Protara Therapeutics, Inc. has initiated a private placement, selling over 9 million shar...

Protara Therapeutics Launches $45M Private Placement Drive

Protara Therapeutics jumps 23% on $45M oversubscribed private financing

Check-Cap, Outset Medical, Vincerx Pharma among healthcare movers

Protara Therapeutics (TARA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein fro...

Buy Rating for Protara Therapeutics' TARA-002 Based on Promising Clinical Data and Market Potential in NMIBC Treatment

ANGO

BDSX

CGON

CHEK

COCH

CVKD

DZSI

HCTI

RGTI

SPRB

VINC

Press Releases

Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ

Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Earnings

Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology

Protara Therapeutics to Participate in Upcoming Investor Conferences

Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

-

-

-

-

-

-

-

25% Off Benzinga's Most Powerful Trading Tools

-

-

-

-

-

-

-

Protara Therapeutics Stock (NASDAQ:TARA), Trade Ideas